Propanc Biopharma, Inc. (PPCB)
USD 5.5
(-25.98%)
USD 5.5
(-25.98%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -1.82 Million USD | 41.84% |
| 2023 | -3.13 Million USD | 6.85% |
| 2022 | -3.36 Million USD | -38.84% |
| 2021 | -2.42 Million USD | 48.95% |
| 2020 | -4.74 Million USD | 17.71% |
| 2019 | -5.76 Million USD | 18.17% |
| 2018 | -7.03 Million USD | 10.53% |
| 2017 | -7.86 Million USD | 16.4% |
| 2016 | -9.41 Million USD | -175.74% |
| 2015 | -3.41 Million USD | -311.39% |
| 2014 | -829.56 Thousand USD | 42.5% |
| 2013 | -1.44 Million USD | 87.38% |
| 2012 | -11.43 Million USD | -431.34% |
| 2011 | -2.15 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -620 Thousand USD | -26.53% |
| 2024 Q3 | -540 Thousand USD | 12.9% |
| 2024 Q4 | -358.57 Thousand USD | 33.6% |
| 2024 Q1 | -490 Thousand USD | 39.51% |
| 2023 FY | -2.66 Million USD | -0.09% |
| 2023 Q1 | -1.01 Million USD | 12.93% |
| 2023 Q4 | -810 Thousand USD | 0.0% |
| 2023 Q3 | -810 Thousand USD | -62.0% |
| 2023 Q2 | -500 Thousand USD | 50.5% |
| 2022 Q3 | -700 Thousand USD | 21.35% |
| 2022 FY | -2.65 Million USD | -31.2% |
| 2022 Q4 | -1.16 Million USD | -65.71% |
| 2022 Q2 | -890 Thousand USD | -45.9% |
| 2022 Q1 | -610 Thousand USD | 47.86% |
| 2021 FY | -2.02 Million USD | 57.27% |
| 2021 Q1 | -430 Thousand USD | -135.83% |
| 2021 Q3 | -420 Thousand USD | -5.0% |
| 2021 Q4 | -1.17 Million USD | -178.57% |
| 2021 Q2 | -400 Thousand USD | 6.98% |
| 2020 Q3 | -2.59 Million USD | -38.5% |
| 2020 Q4 | 1.2 Million USD | 146.33% |
| 2020 FY | -4.74 Million USD | 17.67% |
| 2020 Q1 | -1.49 Million USD | 6.84% |
| 2020 Q2 | -1.87 Million USD | -25.34% |
| 2019 Q2 | -1.45 Million USD | 31.76% |
| 2019 Q3 | -581.85 Thousand USD | 59.87% |
| 2019 Q4 | -1.6 Million USD | -175.25% |
| 2019 FY | -5.75 Million USD | 18.2% |
| 2019 Q1 | -2.12 Million USD | -49.39% |
| 2018 Q3 | -1.49 Million USD | 32.29% |
| 2018 Q2 | -2.2 Million USD | -14.46% |
| 2018 Q1 | -1.92 Million USD | -17.77% |
| 2018 Q4 | -1.42 Million USD | 4.6% |
| 2018 FY | -7.03 Million USD | 10.53% |
| 2017 FY | -7.86 Million USD | 16.4% |
| 2017 Q4 | -1.63 Million USD | -19.14% |
| 2017 Q3 | -1.37 Million USD | 63.54% |
| 2017 Q2 | -3.76 Million USD | -241.29% |
| 2017 Q1 | -1.1 Million USD | 61.44% |
| 2016 FY | -9.41 Million USD | -175.74% |
| 2016 Q1 | -838.89 Thousand USD | 54.07% |
| 2016 Q2 | -3.56 Million USD | -324.61% |
| 2016 Q3 | -2.15 Million USD | 39.59% |
| 2016 Q4 | -2.85 Million USD | -32.79% |
| 2015 Q1 | -783.3 Thousand USD | -259.99% |
| 2015 Q4 | -1.82 Million USD | -302.11% |
| 2015 Q3 | -454.25 Thousand USD | -31.48% |
| 2015 Q2 | -345.47 Thousand USD | 55.89% |
| 2015 FY | -3.41 Million USD | -311.39% |
| 2014 Q3 | -66.86 Thousand USD | -353.29% |
| 2014 FY | -829.56 Thousand USD | 42.5% |
| 2014 Q1 | -571.51 Thousand USD | -154.4% |
| 2014 Q2 | 26.39 Thousand USD | 104.62% |
| 2014 Q4 | -217.58 Thousand USD | -225.41% |
| 2013 Q3 | -337.67 Thousand USD | 12.92% |
| 2013 Q4 | -224.64 Thousand USD | 33.47% |
| 2013 FY | -1.44 Million USD | 87.38% |
| 2013 Q1 | -492.68 Thousand USD | 80.75% |
| 2013 Q2 | -387.75 Thousand USD | 21.3% |
| 2012 Q2 | -2.71 Million USD | 11.79% |
| 2012 Q3 | -3.09 Million USD | -14.16% |
| 2012 Q1 | -3.07 Million USD | -370.33% |
| 2012 FY | -11.43 Million USD | -431.34% |
| 2012 Q4 | -2.55 Million USD | 17.36% |
| 2011 Q3 | -508.43 Thousand USD | -23.61% |
| 2011 FY | -2.15 Million USD | 0.0% |
| 2011 Q4 | -653.68 Thousand USD | -28.57% |
| 2011 Q2 | -411.31 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -36.325% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 73.929% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 103.436% |
| Nascent Biotech, Inc. | -2.08 Million USD | 12.797% |
| Rebus Holdings, Inc. | -1.02 Million USD | -78.483% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 102.795% |
| Qrons Inc. | -789.34 Thousand USD | -130.637% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -187.873% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 97.092% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -338.176% |
| Skye Bioscience, Inc. | -37.64 Million USD | 95.164% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 97.571% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 72.316% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -565.88% |
| SQZ Biotechnologies Company | -79.46 Million USD | 97.709% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 37.058% |
| Mesoblast Limited | -87.95 Million USD | 97.93% |
| Marizyme, Inc. | -65.34 Million USD | 97.214% |
| Genus plc | 7.9 Million USD | 123.045% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 83.285% |
| Pharming Group N.V. | -10.54 Million USD | 82.741% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 16.098% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 50.932% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 79.415% |
| ContraFect Corporation | -65.15 Million USD | 97.206% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 62.74% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -5.388% |
| IMV Inc. | -36.48 Million USD | 95.01% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 77.412% |
| MultiCell Technologies, Inc. | -380.07 USD | -478898.079% |
| ONE Bio Corp. | 8.67 Million USD | 120.982% |
| Accustem Sciences Inc. | -3.74 Million USD | 51.406% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 96.478% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -43.673% |
| Q BioMed Inc. | -2.05 Million USD | 11.284% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 51.232% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 23.535% |
| Biomind Labs Inc. | -1.21 Million USD | -49.922% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 96.952% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 41.307% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 76.964% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 6.604% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -12056.303% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 88.53% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 68.705% |
| GB Sciences, Inc. | -1.36 Million USD | -33.697% |
| Alpha Cognition Inc. | -13.77 Million USD | 86.781% |
| HST Global, Inc. | -146.21 Thousand USD | -1145.146% |
| CSL Limited | 2.64 Billion USD | 100.069% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -3.747% |
| Halberd Corporation | -79.67 Thousand USD | -2184.914% |
| Enzolytics Inc. | -2.17 Million USD | 16.368% |
| Agentix Corp. | -1.37 Million USD | -32.478% |
| Resverlogix Corp. | -3.61 Million USD | 49.57% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 42.596% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.383% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 1957.682% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 126.291% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 54.177% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 39.84% |
| AVAX Technologies, Inc. | -6.41 Million USD | 71.615% |
| Zenith Capital Corp. | -10.59 Million USD | 82.819% |
| Genscript Biotech Corporation | -95.47 Million USD | 98.093% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -7732.923% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 56.089% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -2912.094% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 9.206% |
| Kadimastem Ltd | -3.3 Million USD | 44.956% |
| Helix BioMedix, Inc. | -1.05 Million USD | -72.389% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 52.33% |
| BioStem Technologies, Inc. | -8.48 Million USD | 78.539% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -312.473% |
| LadRx Corporation | 400.44 Thousand USD | 554.628% |
| Cell Source, Inc. | -5.32 Million USD | 65.787% |
| Regen BioPharma, Inc. | 1.02 Million USD | 277.871% |
| Regen BioPharma, Inc. | 1.02 Million USD | 277.871% |
| NovAccess Global Inc. | -4.76 Million USD | 61.827% |
| Affymax, Inc. | -14.42 Million USD | 87.378% |
| Itoco Inc. | -1.86 Million USD | 2.593% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 59.021% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -9.079% |
| Mobile Lads Corp. | -2.26 Million USD | 19.563% |
| CytoDyn Inc. | -49.84 Million USD | 96.347% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -2203.504% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -698.033% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -93.359% |
| SYBLEU INC | -180.3 Thousand USD | -909.699% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -12.884% |
| International Stem Cell Corporation | -131 Thousand USD | -1289.716% |
| Bioxytran, Inc. | -4.28 Million USD | 57.464% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -3254.452% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 28.049% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 96.213% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 13.882% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -133.136% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 42.534% |
| Neutra Corp. | -233.46 Thousand USD | -679.786% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 91.028% |
| PureTech Health plc | -65.69 Million USD | 97.229% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 91.439% |
| IXICO plc | -1.17 Million USD | -54.544% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 81.661% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 96.813% |
| CSL Limited | 2.64 Billion USD | 100.069% |
| Cellectis S.A. | -103.17 Million USD | 98.235% |